Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Santen to Take Another Stab at US Market, Eyes Stand-Alone Sales Force
May 15, 2017
- Astellas Ditches ASP8273 as NSCLC Treatment
May 15, 2017
- Opdivo Drives Ono to Record Profits in FY2016
May 15, 2017
- No Plan for LLP Split-Off at This Point: Sumitomo Dainippon Chief
May 15, 2017
- Sumitomo Dainippon Scores Record Earnings on Latuda Boost
May 15, 2017
- Sales of 4 Japan Drug Majors Dip 3.7% on Stronger Yen, Price Cuts; Global Brands Solid
May 12, 2017
- Daiichi Sankyo Eclipses Takeda, Becomes Top Maker by Japan Ethical Drug Sales
May 12, 2017
- AZ Union Petitions Court to Adjudicate Labor Dispute, Claiming Unfair Demotions and Pay Cuts
May 12, 2017
- Mitsubishi Tanabe to Transfer Production of Medway to Outside Party
May 12, 2017
- Chugai Grants JW Pharmaceutical Marketing Rights for Emicizumab in South Korea
May 12, 2017
- Astellas, Univ. of Tokyo to Expand Research Collaboration on Rice-Based Oral Vaccine
May 12, 2017
- Baxalta Files Patent Infringement Lawsuit against Chugai over Development of Hemophilia A Treatment Emicizumab in US
May 12, 2017
- Mitsubishi Tanabe Eyes M&As for Post-Radicava Strategy in US: President
May 11, 2017
- There Could Be Discussions on Price Reviews for Add’l Indication-Driven Sales Growth: Weber
May 11, 2017
- Mitsubishi Tanabe Sees Bullish Simponi, but Sales Slightly Lower on Price Revision
May 11, 2017
- Shionogi Wants to Zero In on Innovative Drugs, Teshirogi says on LLP Transfer
May 11, 2017
- Shionogi Enjoys Rise in Japan Sales, Profits on HIV Royalty Revenue
May 11, 2017
- Eisai Plans Japan Filing for Lenvima’s HCC Indication in June: CEO
May 11, 2017
- Eisai’s Global Brands Brisk but Sales Slip on Forex, Drug Price Revision
May 11, 2017
- Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows
May 11, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…